Today we look at one noteworthy recent insider buy. On Wednesday, VYNE Therapeutics', Patrick G. Lepore, made a $43,800 buy of VYNE, purchasing 15,000 shares at a cost of $2.92 each. Bargain ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on ...